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Abstract 
Low-carbohydrate diets are being widely recommended, but with apparently conflicting 
evidence. We have conducted a formal systematic review of the published systematic reviews 
of RCTs between low-carbohydrate vs. control (low-fat/energy-restricted) diets in adults with 
overweight and obesity. In MEDLINE, Embase, Web of Knowledge and Cochrane Database of 
Systematic Reviews, searched from inception to September 2017, we identified 12 systematic 
reviews, 10 with meta-analyses. Differences in methods, study-quality, weight-change, and 
citations of published systematic reviews were assessed by AMSTAR-2. Review methods 
varied in definitions of low-carbohydrate, databases searched, and bias assessment. Overall 
review quality was high in two, moderate in three, critically low in seven. Among meta-analyses, 
4/5 with critically low quality showed low-carbohydrate diet superiority for weight loss (0.7-4.0 
kg), while high quality meta-analyses reported little or no difference between diets. Greater 
numbers of participants correlated with smaller differences in weight loss (r=0.73, p=0.03). More 
citations correlated with lower review quality (rho= -0.9, p=0.037), with larger differences in 
weight loss (rho= -0.9, p=0.037), and with journal impact factor (rho=1.0, p=0.01). In conclusion, 
publication acceptance and citations appear to favour apparently larger effect-sizes above 
methodological quality. Better quality reviews and RCTs are needed, before recommending low-
carbohydrate diets as preferred to other approaches for energy restriction.  
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Abbreviations 
LCD, low-carbohydrate diet 
RCT, randomised controlled trial 
LFD, low-fat diet 
TG, triglyceride 
LDL, low-density lipoprotein cholesterol 
CHO, carbohydrate 
PRISMA, Preferred Reporting Items of Systematic reviews and Meta-analyses 
CDSR, Cochrane Database of Systematic Reviews 
BMI, body mass index 
TC, total cholesterol  
HDL, high-density lipoprotein cholesterol 
AMSTAR, A MeaSurement Tool to Assess systematic Reviews 
RoB, risk of bias 
T2DM, diabetes mellitus type 2 
LEARN, Lifestyle, Exercise, Attitudes, Relationships, and Nutrition 
VLCKD, very low-carbohydrate ketogenic diet  
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Introduction  
Low-carbohydrate diets (LCD) have been increasingly used for weight reduction in recent years 
and been heavily promoted in the media and scientific publications (1-3). Public interest in LCD 
might be traced to a letter by William Banting published in 1863, describing his own successful 
weight loss by limiting carbohydrates (CHO) intake (4). It has become popular again recently 
with a plethora of best-selling books providing a weight loss diet by eliminating bread, pasta, 
grains, fruits, starchy vegetables, and liberal consumption of animal protein, fat, cheese, cream 
and butter (5). Evidence for their effectiveness, and whether there is any specific effect other 
than through energy restriction, has however been hotly debated.  
 
Many randomised controlled trials (RCT) have been conducted, with conflicting results. A series 
of systematic reviews and meta-analyses have been conducted to investigate RCT 
methodologies, and to try to establish the effectiveness of LCDs compared to low-fat diets (LFD) 
or energy-restricted weight loss diets (6-11). However, they too have drawn inconsistent 
conclusions. For example, Mansoor et al. (12) showed a greater reduction in body weight and 
triglyceride (TG) in subjects following LCDs compared to LFDs while an apparently similar meta-
analysis reported no difference in weight loss but a rise, or no reduction, in low-density 
lipoprotein (LDL) cholesterol (13). Differences in inclusion and exclusion criteria, or biases 
inherent in the designs of included trials, might contribute to disagreement among published 
meta-analyses. Even the definition of an LCD used may vary, as it can encompass a range of 
CHO intake from 20 to 120 g/day, or 20% to 45% energy from CHO (12-14).  
 
Systematic reviews and meta-analyses are regarded as the final scientific arbiter, essential for 
synthesis of scientific evidence, using comprehensive and reproducible approaches along with 
methodological assessments of the included studies (15). A survey in PUBMED showed a rapid 
increase in publication of systematic reviews and meta-analyses from 1991-2014, more than 
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half of them might be flawed, misleading and unnecessary (16). These factors have accelerated 
an additional design of evidence synthesis - overview of systematic reviews or systematic 
review of systematic reviews, which systematically identify and critically appraise multiple 
systematic reviews and meta-analyses in a single document, aiding clinical decision making and 
guideline development (17). 
 
One of the benefits and purposes of this approach is to compare methods used and assess the 
quality of the included systematic reviews, which could explore the inconsistency of their results 
(17, 18), as in the meta-analyses of effects of LCDs. It is clearly important to eliminate bias in 
conducting and reporting of intervention studies. However, quality assessment of the systematic 
review process, itself potentially open to bias, is also important for evaluating the reliability of 
conclusion, and may be neglected when systematic reviews are cited. 
 
Objectives of the present study were: 1) to document differences in the methods, study-
quality and conclusions of published systematic reviews with meta-analyses; and 2) to evaluate 
the weight loss outcomes reported in meta-analyses, in relation to the quality of published 
systematic reviews.  
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Methods 
Protocol and registration 
The present systematic review of systematic reviews was conducted using the Preferred 
Reporting Items of Systematic Reviews and Meta-analyses (PRISMA) statement (19). A 
systematic review protocol was registered at the PROSPERO with the registration number 
CRD42018072137 (20). 
 
Eligibility criteria 
Papers were eligible if they met the following criteria:  
i. Systematic reviews, with and without meta-analyses, of randomised controlled trials. 
ii. Compared any types of LCDs to control diets (LFDs or energy-restricted diets); papers 
were excluded if the intervention included additional components such as exercise or 
drugs. 
iii. Involved subjects of either sex, with baseline body mass index (BMI) ≥25 kg/m2: papers 
were excluded if the study population included subjects whose BMI less than 25 kg/m2. 
iv. Meta-analyses reported mean differences in weight loss as the primary outcome 
between the two diets, at any length of follow-up.  
v. Limited to English language 
vi. Publication after 2000 until September 2017 
 
The present systematic review thus included systematic reviews involving a variety of LCDs 
such as Atkins Diet, Paleolithic diet, Zone Diet, Sugar Busters, Harcombe, ketogenic diet, very 
low CHO diet, or as stated as included by the authors of each systematic review.  
 
The primary outcome for the present systematic review was mean differences in weight loss 
reported in meta-analyses between LCDs and the control (LFDs or energy-restricted) diets. 
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Secondary outcomes were lipid profile, fasting blood glucose and insulin, blood pressure, 
glucose tolerance test, adverse effects, and the publication and citation metrics of the papers 
included. 
 
Search and Information sources 
We conducted a systematic literature search in electronic databases including MEDLINE 
(OvidSP), Embase (OvidSP), Web of Knowledge and Cochrane Database of Systematic 
Reviews (CDSR). Published conference abstracts and reference lists of included reviews were 
also searched. In order to explore the effects of LCDs on weight loss, the following free-texts 
and MeSH terms were used: low-carbohydrate diet; restricted carbohydrate; very low 
carbohydrate diet; ketogenic diet; Atkins Diet; Paleolithic diet; Zone diet; Sugar Busters diet; 
South Beach diet; Harcombe diet; weight loss; weight reduction; low fat diet; overweight; 
obesity; systematic review; review; and meta-analysis. The full search strategy for MEDLINE is 
available as online supporting information (Table S1). 
 
Study selection 
All identified records from each database were exported to Endnote (Endnote X8, Thomson 
Reuters, New York, USA). Duplicates were excluded. Two authors (CC and MK) independently 
screened and excluded irrelevant titles and abstracts. The remaining potential eligible records, 
including those with disagreement at this step, were then included for full-text screening against 
eligibility criteria. A third author (EC) was consulted over nine cases when there was 
disagreement at the full-text level between the two reviewers, primarily about whether the 
dietary interventions in individual RCTs should be considered LCDs.  
 
Data extraction 
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A data extraction template was created using Microsoft Excel. Two authors (CC and MK) 
performed data extraction independently. Disagreements were resolved by consensus or 
consulting a third author (EC) where there was an issue related to data extraction. The following 
information was extracted:  
1) Systematic review information (e.g. author name, title, year) 
2) Methods of each systematic review (e.g. protocol registration, objective, search strategy 
and databases, inclusion and exclusion criteria, definitions of LCDs and LFDs) 
3) Numbers of included trials and numbers of total participants from each review. 
4) Numerical outcomes of weight loss, TG, LDL, high-density lipoprotein cholesterol (HDL), 
total cholesterol (TC), glucose, insulin, and blood pressure. All measurement units were 
converted to the SI unit. 
5) Numbers of citations in SCOPUS and in Google Scholar, 3 years after publication. 
6) Funding sources for each review and potential conflict of interest of review authors. 
 
Quality assessment 
Two authors independently performed quality assessment of included reviews using ‘A 
MeaSurement Tool to Assess systematic Reviews 2’ (AMSTAR 2), disagreements were solved 
by consensus or consulting the third author (21). As suggested by Shea et al., critical domains 
or items of the tool were identified, for evaluating and classifying the included studies, as well as 
total score (21). Critical domains where errors or biases would seriously affect the validity of 
conclusions of the included reviews were identified as following (Item 4, 9, 11-15; Table 1):  
i. Items relating to comprehensive literature searching,  
ii. Statistical analysis of combined result including investigating causes of heterogeneity,  
iii. Methods of the risk of bias (RoB) assessment,  
iv. The impact of RoB on pooled results, discussion and conclusion, 
v. Assessment of publication bias.  
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We rated the overall quality of the included reviews as following (Table 1):  
 ‘high’ methodological quality if the included reviews did not contain any of critical 
domains but could have up to 3 non-critical domains;  
 ‘moderate’ if had more than 3 non-critical domains;  
 low if had one critical domain; and  
 ‘critically low’ if had more than one critical domains.  
 
A total quality score was also applied to each review. One point for each AMSTAR item was 
given if included review met the answer ‘Yes’, 0.5 point for ‘Partial Yes’, and no point for ‘No’. A 
full total score of 13 is for systematic reviews without meta-analysis, and of 16 for systematic 
reviews with meta-analyses.  
 
Data synthesis 
A narrative synthesis was used to describe reviews’ characteristics, method, quality and their 
conclusions. Because the meta-analytic technique is to increase statistical power by increasing 
sample size, published meta-analyses with fewer studies and small sample size could influence 
the magnitude of effect size (15). Therefore, correlations between ‘weight loss effect size’ and 
numbers of primary studies, and numbers of subjects (from each meta-analysis) were 
investigated using Pearson’s correlation coefficient after scatter plot suggesting of potential 
linear relationship pattern. In addition, a correlation between ‘weight loss effect size’ and quality 
score was analysed by Spearman’s rank correlation. Spearman’s rank correlation coefficient 
was also used to investigate whether the popularity (citation count) of published meta-analyses 
is related to the highest quality of the meta-analysis, to the ‘weight loss effect size’, or the 
reputation (impact factor) of the journal.   
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Results 
Identification of systematic reviews 
We retrieved 235 records from literature searching. After duplicates were removed, 201 titles 
and abstracts were screened for inclusion, resulting in 39 full-text articles to be assessed for 
eligibility. Excluded full-texts with reasons are presented in Table S2. A total of 12 systematic 
reviews, 2 without meta-analysis (22, 23) and 10 with meta-analyses (10, 12-14, 24-29), were 
included for data synthesis and quality assessment (Figure 1). 
 
Systematic reviews without meta-analyses: methods, quality and outcomes 
The characteristics of the two systematic reviews without meta-analysis are summarised in 
Table 2 and 3. All of them included primary studies with LCDs in participants with overweight 
and obesity, one reported weight loss and HbA1c outcomes (22) while the other reported only 
weight loss outcome (23). None of them reported adverse effects. Both systematic reviews did 
not report information about their written protocols, performing study selection and data 
extraction in duplicates, and RoB assessment, resulting in a judgement of critically low quality 
for these two reviews, Table 6. 
 
A systematic review by Castaneda-Gonzalez et al. (22) aimed to evaluate effects of LCDs on 
weight loss and glycaemic control in participants with type 2 diabetes mellitus (T2DM), 
compared to various controls including LFDs, usual care diets, or low glycaemic diet. The 
review authors defined LCD as maximum intake of CHO less than 130 g/day and included only 
RCTs as study design. Eight studies were included for this systematic review, but one of them 
was not an RCT (30). This review also reported an incorrect amount of CHO intake of one RCT 
(31). Among eight included studies, five reported weight loss outcomes. Three studies, of 3-4 
months, found significantly greater weight loss with LCDs (3.1 to 11.1 kg from baseline) 
compared to control diets (0.8 to 6.9 kg from baseline). In contrast, two studies with longer 
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duration (1-2 years) found no significant differences in weight loss between the two diets (LCDs, 
3.1 to 3.8 kg vs. LFDs, 3.1 to 3.2 kg, from baseline). Regarding HbA1c, LCDs decreased HbA1c 
by 0.02 to 1.5% as did LFD by 0 to 0.5%, however, these effects were inconsistent. Only 2 out 
of 6 RCTs showed significantly greater reductions in HbA1c following LCDs compared to LFDs 
(22). 
 
The other systematic review without meta-analysis, by Dutton et al. (23), evaluated the effects 
on weight loss of diet composition, use of food provision and modality of treatment delivery. 
Only PubMed was searched. Among included studies, 10 RCTs of LCD interventions compared 
to various types of control diets (e.g. LFD, Mediterranean diet, or commercial diets: LEARN, 
Ornish, Zone diet), but the LCD was not defined in the inclusion criteria. Participants of included 
RCTs had BMI greater than 25 kg/m2 with and without co-morbidities. Duration of intervention 
ranged from 2 to 12 months with follow-up periods up to 48 months. The authors concluded that 
LCDs might result in greater weight reduction over LFDs for a short period, but this was not 
consistent among studies. Most studies failed to show benefit for one diet or the other over a 
longer follow-up (23). 
 
Systematic reviews with meta-analyses 
The characteristics of the ten meta-analyses are summarised in Table 4 and 5. All aimed to 
evaluate the effectiveness of LCDs compared to LFDs on weight reduction and metabolic 
parameters. One meta-analysis by Johnston et al. used a network meta-analysis for pooled 
results (29). 
 
Participants 
All meta-analyses included RCTs among participants with overweight and obesity, with and 
without co-morbidities that included type 2 diabetes, hypertension, dyslipidaemia, cancer, 
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polycystic ovarian syndrome, and others. One meta-analysis included RCTs conducted solely 
among self-reported ‘healthy’ participants (12). The meta-analysis by Naude et al. (13) 
performed an analysis between participants with and without diabetes separately. (Table 4) 
 
Interventions 
The definition of LCD varied among meta-analyses: four included LCD with CHO <60g/day or 
<20% energy per day, while another five included LCD with CHO <120 g/day or up to 45% 
energy per day. One meta-analysis did not define LCD other than as declared by the RCTs’ 
authors (26). Among these meta-analyses, one focused solely on commercial weight loss diets, 
which included Atkins, Zone, South Beach, Ornish, Rosemary and LEARN diets (29); and 
another one used the term ‘very low carbohydrate ketogenic diet’ (VLCKD) which included CHO 
less than 50 g/day (25). Nine meta-analyses used LFDs as comparators, which comprised of 
less than 30% energy contribution from fat. Another one (13) used isocaloric balanced weight 
loss diet (CHO:Fat:Protein; 45-65:25-35:10-20% of energy) as a comparator to LCD, which 
explored the effectiveness of LCD on weight reduction when the energy intake was equal to that 
of a ‘balanced’ weight loss diet. (Table 4) 
 
Search methods of included meta-analyses 
MEDLINE was the most searched database (n=10), followed by EMBASE (n=7) and CDSR 
(n=4). Five meta-analyses searched trial registries (e.g. Clinicaltrials.gov; The Cochrane Central 
Register of Controlled Trials, CENTRAL). Two meta-analyses searched only one database (14, 
24). Numbers of included RCTs from each meta-analysis ranged from 5 to 48 RCTs comprising 
of 447 to 7286 participants. (Table 5) 
 
Methodological quality of included meta-analyses 
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Methodological quality assessment is presented in Table 6. According to AMSTAR 2 items 
described in the method section, all published meta-analyses described their research question 
or objectives following the PICO (Item 1). Most of the included meta-analyses conducted a 
comprehensive literature search, and performed study selection and data extraction in duplicate 
(Item 3-6). The AMSTAR 2 items that most of the meta-analyses failed to meet were the 
following: protocol registration (Item 2); provide a list of excluded RCTs with justification (Item 
7); and report on the source of funding for the included RCTs (Item 10). 
 
Critical Domains: Four meta-analyses assessed the RoB using the Cochrane Collaboration Risk 
of Bias Tool, three assessed only some items of this tool, while the rest of the meta-analyses 
did not report RoB assessment. Six meta-analyses assessed or discussed the impact of RoB on 
pooled results. Four meta-analyses did not plan to investigate the causes of heterogeneity 
resulting in the answer ‘No’ for item 11 – appropriate methods for statistical combination of 
results; and item 14 – explain/discus heterogeneity observed in the results of the review. Eight 
out of ten meta-analyses investigated the publication bias. 
 
Overall quality rating: Methodological quality of included meta-analyses was classified by the 
AMSTAR 2 method as ‘critically low’ for five out of ten meta-analyses (14, 24, 26-28), 
‘moderate’ for three (10, 12, 29) and ‘high’ for two meta-analyses (13, 25). (Table 4) 
 
Reported risk of bias of primary RCTs 
Of four meta-analyses that assessed all items of the RoB tool, allocation concealment and 
blinding outcome assessment were judged as unclear to high RoB. Incomplete outcome data 
were also judged as high RoB across the included RCTs.  
 
Attrition rates and adherence 
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Attrition rates were high, and varied across the RCTs. Attrition rates in LCD groups ranged from 
apparently zero to 60% of participants as did as control diets from 0 to 54%. A meta-analysis by 
Naude et al. (13) calculated adherence scores for macronutrient goals in LCD and an isocaloric 
balanced weight loss diet. The scores varied among primary RCTs. At 3-6 months, of 13 RCTs, 
4 showed similar adherence to prescribed macronutrient goals in the two diets, 5 showed better 
adherence scored with LCD and 4 showed better adherence with a balance weight loss diet. In 
contrast, at 12 months, 3 RCTs showed better adherence with LCD while 5 RCTs showed better 
adherence with a balanced weight loss diet intervention (13). 
 
Publication bias, funding sources of meta-analyses and authors’ conflict of interests 
Only eight meta-analyses assessed the publication bias using funnel plot or statistical test. 
Weight loss outcome was subject to publication bias in seven out of 8 meta-analyses, Table 5. 
Four meta-analyses (three of critically low; one of moderate quality) and/or their authors were 
supported by commercial organisations, as well their pooled results showed a superiority of 
LCDs over LFDs. Another four meta-analyses (one of critically low; two of moderate; one of high 
quality) were supported by non-commercial organisations such as university or research 
institutes, while the rest reported no funding or no conflict of interest. (Table 5 and 7) 
 
Effect of intervention on weight reduction 
Five meta-analyses synthesised pooled effects at 6 and 12 months, one at 12 months, and four 
synthesised their results regardless of the duration of intervention (2-24 months). At 6 months, 
evidence from a high methodological quality meta-analysis by Naude et al. (13), comparing 
LCDs (<45%E from CHO) with isocaloric balanced diets, demonstrated no difference in weight 
loss outcome between the two diets. Two moderate quality meta-analyses showed contrary 
results as following: a network meta-analysis (<40%E CHO) by Johnston et al. (29) reported no 
difference in weight loss while another meta-analysis by Nordmann et al. (10) reported a 
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significantly greater weight change of -3.3 kg following LCD (<60g CHO) compared to LFD 
(mean weight change following LCD minus LFD, negative value indicates subjects lost more 
weight following LCD than those who followed LFD; I2=65%, p=0.02). Two critically low quality 
meta-analyses (24, 27) reported a significantly greater weight change following LCD compared 
to LFD from -1.4 to -4.0 kg with significantly high heterogeneities (I2=65-91%). 
 
At 12 months, three out of six meta-analyses (two of critically low; one of high quality) reported a 
greater weight change in LCD, by -0.77 to -1.0 kg compared to LFD (I2=0-48%). Generally, 
meta-analyses with significant results favouring LCDs included RCTs with CHO <60g/day, 
whereas three out of five meta-analyses with CHO contributing toward up to 45% energy 
showed no difference in weight loss between the two diets. (Table 7) 
 
Serum Triglyceride and cholesterol 
Seven meta-analyses reported mean differences in TG, LDL and HDL-cholesterol outcomes, 
and six for TC outcome, Table S3-S6. None of them reported whether the differences in these 
outcomes, in their included RCTs, were adjusted to weight loss. A high quality meta-analysis by 
Naude et al. of LCD vs. isocaloric balanced diet reported no difference in mean reduction in TG 
and TC between the two diets. A subgroup analysis, however, showed that participants without 
diabetes assigned to LCD had increased LDL-cholesterol at 6 months greater than LFD (0.09 
mmol/l; 95%CI 0.0 to 0.18; I2=32%, p=0.14; 12 trials), and had increased HDL-cholesterol at 12 
months (0.04 mmol/l; 95%CI 0.01 to 0.08; I2=35%, p=0.16) (13). 
 
In contrast, another high quality meta-analysis by Bueno et al. demonstrated a greater reduction 
in TG level following VLCKD than LFD (-0.18 mmol/l; 95%CI -0.27 to -0.08; I2=12%, p=0.33; 12 
trials), but a significant rise in LDL-cholesterol (0.12 mmol/l; 95%CI 0.04 to 0.20; I2=0%, p=0.70) 
(25). Consistent findings of decreased TG but increased LDL-cholesterol following LCDs were 
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also reported across the remaining meta-analyses, regardless of duration and amount of CHO 
intake. Mean difference in changes in HDL-cholesterol between LCDs and LFDs increased in 5 
out of 7 meta-analyses by 0.04-0.14 mmol/l (I2=0-78%) while TC showed inconsistent results. 
 
Glucose, insulin, HbA1c and blood pressure 
There was no difference in reduction in glucose (5 meta-analyses), insulin (3 meta-analyses) 
and HbA1c (2 meta-analyses) between the two diets, Table S7-S9. No meta-analyses reported 
whether the differences in these outcomes were adjusted to weight loss. Seven meta-analyses 
reported mean differences in SBP, and six meta-analyses for DBP, Table S10-S11. No 
significant differences in effects on systolic and diastolic blood pressure were reported at 6 
months. At 12 months, one meta-analysis, of critically low quality (27), LCDs showed a greater 
reduction in SBP by 2.19 mmHg (95%CI -4.35 to -0.03; I2=28%, p=0.23). In addition, another 
one meta-analysis, of high quality (25), demonstrated a greater reduction in DBP by 1.43 mmHg 
(95%CI -2.49 to -0.37; I2=3%, p=0.41) following VLCKD compared to LFDs. 
 
Adverse effects 
Only one meta-analysis, of moderate quality, reported adverse effects of LCDs, including 
constipation, headache, halitosis, muscle cramp and general weakness (29). 
 
Correlations between weight loss effect size, quality score, number of studies and number of 
subjects 
Network meta-analysis (29) was excluded from this analysis, as there was no direct comparison 
of interventions. Nine meta-analyses were analysed for correlation. Mean differences in weight 
loss between LCD vs. LFD were positively correlated with quality score, number of primary 
studies and number of participants in each meta-analysis, (Table 9). Among these meta-
analyses, greater numbers of participants were significantly correlated with smaller mean 
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differences between the two diets (r=0.73, p=0.03), suggesting that bigger reported differences 
were more likely to be chance findings. 
 
Correlations between citation number, weight loss effect size, quality, and impact factor. 
Citation numbers of each meta-analysis from Scopus and Google Scholar are demonstrated in 
Table 10. Only five meta-analyses had citations up to 3 years. Correlation analysis showed that 
a higher number of citations of a meta-analysis was correlated with a lower quality score (lower 
ranking methodological quality; rho= -0.9, p=0.037); and citation number was associated with 
larger mean differences in weight loss between LCD and LFD (rho= -0.9, p=0.037). 
Undoubtedly, citation number was strongly correlated with the impact factor of the journal (rho= 
1.0, p=0.01). These analyses suggest that acceptance of a meta-analysis by a major (high 
impact factor) journal, and subsequent citation, are more influenced by the apparent effect size 
reported than by the quality of the research.  
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Discussion 
At their inception, a systematic review was considered an almost infallible route to definitive 
knowledge, based only on well-designed scientific research with little or no RoB or error. 
However, it is clear that well-conducted systematic reviews can in fact draw differing 
conclusions for the same research questions. The present paper has attempted to conduct a 
systematic review and quality assessment of existing systematic reviews of the published 
evidence, on a topic of enormous scientific debate and public interest. It explores the 
differences between the conclusions of existing systematic reviews, and the factors which might 
contribute to biasing systematic reviews one way or the other. 
 
Published systematic reviews have a substantial variation in their methods, which included the 
definition of LCD, number of databases searched, RoB assessment, and investigation of causes 
of heterogeneity. This variation contributed to differences in methodological quality and their 
synthesised results. Most meta-analyses are of rather low methodological quality regarding 
critical domains of AMSTAR 2 tool: lack of assessment of the RoB and impact of RoB on the 
pooled results, and lack of appraisal of the drivers of heterogeneity.  
 
Adopting LCD involves excluding usual high-CHO foods, thus inevitably reducing energy intake, 
but without specifically counting or restricting energy intake. Definition of LCD remains an issue 
when communicating the effects of LCD. The cut-off ranges from <60g/day to <45%E as the 
latter cut-off may regard to dietary guidelines that recommend CHO intake for 45-65% of daily 
energy intake. Meta-analyses with more extreme CHO restriction (<60g/day), and shorter 
duration (6 months follow-up) reported significantly greater weight loss than LFD/energy-
restricted control diets. The weight loss effect attenuated when the amount of CHO increased or 
the longer follow-up. This could be from losing adherence to the prescribed diet, in both groups 
of intervention. Losing adherence to diets or high attrition rate are major problems in all nutrition 
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research among free-living subjects (32, 33). Combining behavioural therapy and frequent 
follow-up could help increase adherence and lower attrition rate (32, 34). 
 
Critically low quality meta-analyses showed a superiority of LCD for weight loss while moderate 
quality showed inconsistent results, and high quality showed little or no difference. This is also 
demonstrated by the association between a high quality ranking and a limited mean difference 
in weight loss between LCD vs. LFD. In addition, nine out of ten meta-analyses’ results were 
subject to publication bias favouring the LCD, which might be from the inclusion of RCTs with 
small sample size and positive results tend to be published (35). However, we found that higher 
numbers of participants were significantly correlated with lower mean differences in weight loss 
between LCD vs. LFD. This does not mean that there is no publication bias in meta-analyses 
with larger sample size, but it could be because these meta-analyses with larger sample size 
included larger RCTs with lower risk of small-study errors, leading to less bias in the meta-
analysis results (36). 
  
A high quality meta-analysis of VLCKD vs. LFD reported a greater weight loss with VLCKD of 
0.9 kg at 12 months (25). This difference, however, is small and may not infer clinical 
significance favouring LCD over LFD. Differences up to about 2kg in body weight could be a 
result of depleted glycogen storage with LCD rather than body-fat loss, an effect which may 
develop at 12-months after 2-3 days re-adherence to LCD (37). Notably, another high quality 
meta-analysis reported no difference in weight loss between LCD and isocaloric balanced 
weight loss diet when the energy intakes of the two diets were equally prescribed (13). Similar 
findings from two large RCTs with 811 and 609 participants, followed up for 1-2 years, 
confirmed that reduced energy intake, with varying macronutrient composition, produced similar 
weight loss (38, 39). This supports the basic Newtonian principle of energy balance; weight loss 
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occurs when energy intake is less than energy expenditure regardless of macronutrient 
composition of the diets (40). 
 
Together, it appears that LCDs are as effective as low-fat diets for inducing weight reduction. 
Both diets, applied in free-living subjects, can reduce body weight by approximately 3 to 10 
kilograms below baseline (11, 13, 38). This amount of weight loss often has some clinical 
benefits (41), but the effect of LCD on increasing LDL is of concern, albeit balanced by reducing 
TG level better than LFD. Variations in these effects probably depend on the profile of other 
nutrients in diets consumed. Most of the reviews concluded that LCD could be used alternatively 
to LFD for weight loss, but they did not mention any of potential concern of increased LDL-
cholesterol in their conclusions, or propose how to avoid this problem, (Table 11). Low CHO 
dieters may have unlimited intake of fat and protein, including animal-sourced, with long-chain 
saturated fatty acids which elevate LDL-cholesterol (42). This is in keeping with longer term 
observational studies reporting detrimental effects of LCDs, increasing risk of CVDs and 
mortality (43-46). 
 
It is of concern that the present study found that only one of the meta-analysis included reported 
adverse effects (29). One patient with type 2 diabetes assigned to LCD arm had poor 
adherence to medication and died in hyperosmolar coma (47). There are many other potential 
hazards reflected by case reports of LCDs, including Wernicke’s encephalopathy (48) and optic 
neuropathy (49) from thiamine deficiency, acute coronary syndrome (50, 51), keto-acidosis (52) 
and anxiety disorder (53). 
 
Quality of included meta-analyses and their included RCTs 
Strengths of included meta-analyses include the use of PICO to formulate their research 
questions or objectives of their reviews, using a comprehensive literature search, conduct a 
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study selection and data extraction in duplicates, and assessing a publication bias. 
Nonetheless, limitations still exist. Most of them did not report on developing or registering a 
protocol for their reviews, this could lead to publication bias as they could change data synthesis 
later to suit their interest (54). Another critical concern is assessing the RoB of included RCTs 
and impact of the RoB on pooled results as this may limit the validity of their conclusion in both 
overestimation and underestimation of the true effects (55).  
 
Among meta-analyses that reported the RoB in included RCTs, the quality of included RCTs 
varied. The primary sources of bias included inadequate reporting of randomisation methods, 
allocation concealment, lack of blinding outcome assessment and high attrition rate. Although 
there are two meta-analyses judged as high quality reviews, their pooled results comprised 
RCTs with mostly high RoB, resulting in limiting the reliability and downgrading the confidence 
of their results to make a recommendation for guidelines. In addition, interpretation of pooled 
results should be cautious, as there was publication bias for weight loss and CVD risks across 
published meta-analyses. 
 
All the meta-analyses included which had funding support declared that the funding body was 
not involved in any part of the conduct of systematic reviews or meta-analyses. However, our 
analysis indicates that funding from a commercial company, or potential conflicts of authors, 
were more evident for those which favoured LCDs rather than LFDs (4 out of 7 meta-analyses), 
and 75% of these meta-analyses are also of critically low quality, (Table 7). More importantly, a 
meta-analysis by Naude et al. also found that results from six out of 19 included RCTs were 
influenced by funders (13). It is always difficult to assess whether funders or conflict of interests 
of authors influence nutritional study outcomes. A meta-analysis by Chartres et al. 
demonstrated that outcomes of nutritional studies were more likely to favour industrial sponsors, 
but that did not reach statistical significance (56). 
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Impact of published meta-analyses on scientific literature (Scopus and Google Scholar) 
Our correlation analysis found that the systematic reviews and meta-analyses with more 
citations were those published in journals with higher impact factor, but they were papers 
indicating larger effect size, and worryingly they were papers with lower methodological quality. 
There is intense scientific debate and media interest in the effects of LCDs, and an apparently 
greater effect size appears to be overcoming the need for high quality methodology in accepting 
meta-analyses for publication, and for their subsequent citation as evidence.  
 
Strength and limitation of the present systematic review process 
We conducted a review following a written protocol. This systematic review of reviews 
addresses concordance and discordance in the results of published systematic reviews and 
meta-analyses. The high quality reviews were highlighted and put together in a single place 
providing definitive summaries (17). The use of AMSTAR tool provided detailed quality 
assessment as its items involves the rigorous and transparent steps for conducting a systematic 
review, and assesses the domains that can produce any biases to the pooled results (21). 
 
Our correlation analyses, examining citations of published systematic reviews has revealed 
patterns which may be worrying, but we have not attempted to assess the purposes of the 
documented citations or the interpretations of the results or their influence on practice or policy. 
The present systematic review of reviews found that only two out of ten meta-analyses are high 
methodological quality. This highlights the problem that most of systematic reviews could be 
flawed. Policy decisions should be able to assess the methodological quality before making any 
recommendations about adopting interventions in clinical practice (16). 
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We have not attempted any meta-analysis of the published systematic reviews: overlapping of 
the included RCTs would distort results (18). Our narrative synthesis is a more appropriate way 
to synthesise results to compare and contrast their methods, quality and conclusions (17). 
Variables that could influence differences in weight loss between LCD and LFD reported in 
meta-analyses include the amounts of CHO, duration of intervention, number of subjects and 
the quality (and possible biases) within the review. However, it is impossible to conduct a 
multivariable analysis on these predictors because of the small numbers of meta-analyses 
available. 
 
Implications for practice 
The present analysis suggests that LCDs are as effective as LFDs or energy-restricted diets for 
weight loss in individuals with obesity, but there is some potential risk of unfavourable lipid 
outcomes with LCDs. The simplicity of LCD makes it easy to follow, but the adherence and 
attrition rates are similar to more conventional weight loss diets. Although most of the published 
meta-analyses recommended that LCD could be an alternative approach for weight reduction, 
we could not make any recommendation for or against the use of LCDs, based on 
methodological quality, risk of increased LDL-cholesterol and importantly, long-term evidence of 
clinical outcomes.  
 
Implications for research 
It is clear that long term studies with clinical outcomes, not just surrogate markers, are needed. 
More information about effects of LCD other than metabolic outcomes is also needed especially 
potential harms such as micronutrient status, bone mineral density and certain type of cancer 
related to low wholegrain, fibre, or fruits intakes.  
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This review also highlights potential areas for improving quality of future RCTs by reporting 
greater details of randomisation process, allocation concealment, blinding outcome assessment 
and the process to overcome high attrition and low adherence. In addition, conducting a 
systematic review and meta-analysis of intervention can be improved. We would encourage 
following guidelines such as the Cochrane Handbook, or Center for Reviews and Dissemination 
guidance. The RoB assessment and impact of the RoB in pooled results must be reported and 
discussed, as this is one of most critical components that could impact on the reliability of the 
results. Including well-conducted RCTs in well-conducted systematic reviews and meta-
analyses remains the best approach to define practice and policy. 
 
Conclusion 
Published meta-analyses of LCD vs. LFD on weight loss have substantial variation in methods 
and quality. Reporting of adverse effects is scarce. Most meta-analyses are of rather low 
methodological quality. Higher quality meta-analyses reported little or no difference in weight 
loss between the two diets, but publication and citations appear to favour those with apparently 
large effect-sizes above methodological quality. To aid decision-making, well-conducted 
systematic reviews of well-conducted RCTs, with reporting of the adverse effects are needed.  
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Table Legends: 
Table 1. AMSTAR 2 items (21) 
Table 2. Characteristics of systematic reviews without meta-analyses 
CHO, carbohydrates; RCT, randomised controlled trial. 
 
Table 3. Methods of included systematic reviews without meta-analyses 
LCD, low-carbohydrate diet; RCT, randomised controlled trial. 
 
Table 4. Characteristics of included systematic reviews with meta-analyses 
BMI, body mass index; CHO, carbohydrates; HP, high protein; LCD, low-carbohydrate diets; 
VLCKD, very low-carbohydrate ketogenic diets; LFD, low-fat diets; LEARN, Lifestyle, Exercise, 
Attitudes, Relationships, and Nutrition diets. 
 
Table 5. Methods of included systematic reviews with meta-analyses 
WOS, Web of Science; CDSR, Cochrane database for systematic reviews; DARE, Database of 
Abstracts of Reviews of Effectiveness; RCT, randomised controlled trial; LCD, low-carbohydrate 
diet; BW, body weight; TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein 
cholesterol; HDL, high-density lipoprotein cholesterol; NIH, National Institute of Health; MRC, 
Medical research council. 
1. Jonathan Sackner-Bernstein owns and may receive compensation from ExVivos, LLC. 
ExVivos, LLC provided payment to authors (DK and SK) for their role as contractors to ExVivos, 
LLC. 
2. Mai Asano, Masahiro Yamazaki and Michiaki Fukui have received grants, honoraria and 
research supports from AstraZeneca plc., Astellas Pharma Inc., Nippon Boehringer Ingelheim 
Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Kyowa Hakko Kirin Company Ltd., Kissei 
Pharmaceutical Co., Ltd., MSD K.K., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk 
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Pharma Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Sanofi K.K., Ono Pharmaceutical Co., Ltd. 
and Takeda Pharmaceutical Co., Ltd. 
 
Table 6. Quality assessment and overall rating judgement of published systematic 
reviews with meta-analyses 
MA, meta-analysis 
 
Table 7. Weight loss outcome (kilograms) 
LCD, low-carbohydrate diet; LFD, low-fat diet; CHO, carbohydrates; E, energy; F, fat; P, protein; 
VLCKD, very low-carbohydrate ketogenic diet; T2DM, type 2 diabetes mellitus. 
a Weight loss are shown in mean difference between LCDs and LFD/energy-restricted diets with 
95% confidence interval in parenthesis. Values represent mean weight change in LCD minus 
mean weight change in LFD; negative values indicate subjects following LCD lost more weight 
than those who followed LFD. 
b Results from network meta-analysis, heterogeneity was calculated from direct comparison of 4 
trials comparing LCD vs. LFD at 12 months, I2=85.5%. 
 
Table 8. AMSTAR quality, number of studies, number of subjects and effect size 
a excludes one study of network meta-analysis due to indirect comparison of interventions 
b for meta-analysis with multiple time-points (e.g. 6 and 12 months) or population (e.g. with and 
without diabetes), the mean difference from highest number of included RCTs was presented 
and used for correlation coefficient analysis. 
c values represent mean weight loss in LCD minus mean weight loss in LFD; negative values 
indicate subjects following LCD lost weight greater than those who followed LFD. 
d Spearman’s rank correlation coefficient analysis 
e Pearson’s correlation coefficient analysis 
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Table 9. AMSTAR quality, effect size and citation counts 
a for meta-analysis with multiple time-points (e.g. 6 and 12 months) or population (e.g. with and 
without diabetes), the mean difference from highest number of included RCTs was presented 
and used for correlation coefficient analysis. 
b values represent mean weight loss in LCD minus mean weight loss in LFD; negative values 
indicate subjects following LCD lost more weight than those who followed LFD. 
 
Table 10. Correlation coefficient between 3-year citation counts and quality, mean 
difference in weight loss, and impact factor. 
 
Table 11. Conclusions from systematic reviews with meta-analyses of LCD vs. 
LFD/energy-restricted diets 
LCD, low-carbohydrate diet; LFD, low-fat diet; CVD, cardiovascular disease; VLCKD, very low-
carbohydrate ketogenic diet; TG, triglyceride; LDL, low-density lipoprotein; HDL, high-density 
lipoprotein; ASCVD, atherosclerotic cardiovascular disease. 
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Figure legend: 
Figure 1. Flow diagram of study selection process 
WoS, Web of Sciences; CDSR, Cochrane database for systematic reviews 
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Table 1. AMSTAR 2 items (21) 
Critical domains 
 Item 4. Did the review authors use a comprehensive literature search strategy?  
 Item 9. Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in 
individual studies that were included in the review?   
 Item 11. If meta-analysis was performed did the review authors use appropriate methods for statistical 
combination of results?  
 Item 12. If meta-analysis was performed, did the review authors assess the potential impact of RoB in 
individual studies on the results of the meta-analysis or other evidence synthesis?  
 Item 13. Did the review authors account for RoB in individual studies when interpreting/ discussing the 
results of the review?  
 Item 14. Did the review authors provide a satisfactory explanation for, and discussion of, any 
heterogeneity observed in the results of the review?  
 Item 15. If they performed quantitative synthesis did the review authors carry out an adequate 
investigation of publication bias (small study bias) and discuss its likely impact on the results of the 
review? 
Non-critical domains 
 Item 1. Did the research questions and inclusion criteria for the review include the components of PICO? 
 Item 2. Did the report of the review contain an explicit statement that the review methods were 
established prior to the conduct of the review and did the report justify any significant deviations from the 
protocol?  
 Item 3. Did the review authors explain their selection of the study designs for inclusion in the review? 
 Item 5. Did the review authors perform study selection in duplicate?  
 Item 6. Did the review authors perform data extraction in duplicate?  
 Item 7. Did the review authors provide a list of excluded studies and justify the exclusions? 
 Item 8. Did the review authors describe the included studies in adequate detail?   
 Item 10. Did the review authors report on the sources of funding for the studies included in the review? 
 Item 16. Did the review authors report any potential sources of conflict of interest, including any funding 
they received for conducting the review? 
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Table 2. Characteristics of systematic reviews without meta-analyses 
Authors Population/ Condition Pre-specified low-carbohydrate diets 
Pre-specified control diets (low-fat or energy 
restricted diets) 
Duration of 
intervention 
Castaneda-
Gonzalez 2011 
(22) 
Adults with Type 2 diabetes Maximum intake of 130 g of CHO per day No, defined as RCTs’ authors definition at least 12 
weeks or 4 
months 
Dutton 2014 
(23) 
Adults with overweight/obesity as defined 
by trials authors 
No, defined as RCTs’ authors definition No, defined as RCTs’ authors definition at least 2 
months 
CHO, carbohydrates; RCT, randomised controlled trial. 
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Table 3. Methods of included systematic reviews without meta-analyses 
Authors Databases 
Search time 
frame 
Included 
studies 
No. of 
subjects 
Risk of Bias Assessment Publication bias 
Funding 
source 
Authors’ 
declaration 
Castaneda-
Gonzalez 2011 
(22) 
PubMed, Cochrane and EBCOhost 1 Jan 2000 to 
1 Jan 2010 
8 664 Assessed randomization process, 
and intention to treat as part of 
quality assessment. 
N/A Did not 
report 
Did not report 
Dutton 2014 
(23) 
PubMed Jan 2003 to 
April 2014 
10 RCTs of 
LCD 
intervention 
N/A Did not perform/report N/A Did not 
report 
No conflict of 
interest 
LCD, low-carbohydrate diet; RCT, randomised controlled trial. 
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Table 4. Characteristics of included systematic reviews with meta-analyses. 
Authors Population/ Condition Pre-specified low-carbohydrate diets 
Pre-specified control diets (low-fat or energy 
restricted diets) 
Duration of 
intervention 
Nordmann 
2006 (10) 
BMI ≥ 25 kg/m2 Maximum intake of 60 g of CHO per day 
without energy intake restriction 
Maximum of 30% of the daily energy intake from 
fat with energy intake restriction 
at least 6 
months 
Hession 2009 
(27) 
Mean or median BMI of 28 kg/m2 • HP ‘ketogenic’ diet, CHO content was less 
than 40 g/day, irrespective of energy content. 
• LCDs, CHO 60 g/day. 
LFD (30% or less daily energy from dietary fat) – 
600 kcal deficit diet. 
at least 6 
months 
Hu 2012 (28) Adults with overweight/obesity as defined 
by trials authors 
≤45% of energy from CHO ≤30% of energy from fat at least 6 
months 
Bueno 2013 
(25) 
Mean BMI > 27.5 kg/m2 VLCKD (i.e. a diet with no more than 50 g 
CHO/day or 10% of daily energy from CHO) 
Restricted-energy diet with less than 30 % of 
energy from fat 
> 12 months 
Johnston 2014 
(29) 
BMI ≥ 25 kg/m2 Atkins, South Beach, Zone; ≤40%CHO, 
approximately 30%Protein, 30-55%Fat 
Ornish, Rosemary Conley; 60%CHO, 10-
15%Protein, ≤20%Fat 
3 months or 
Longer 
Naude 2014 
(13) 
Adults with overweight/obesity 
have diabetes, glucose intolerance or 
insulin resistance, cardiovascular 
conditions or risk factors such as 
hypertension and dyslipidaemia, as 
defined by trial authors 
<45%CHO: 
a) low CHO, high fat, high protein diet (high 
fat variant) or  
b) low CHO, recommended fat, high protein 
diet (high protein variant)  
Control diets were balanced weight loss diet 
plans - energy restriction, Fat 25-35%, CHO 45-
65%, Protein 10-20% 
12 weeks up 
1) 3-6 months 
2) 1-2 years 
Alexandraki 
2015 (24) 
BMI ≥ 25 kg/m2 <45% of energy from CHO; Atkins, Zone 
diets. Some studies had 2 interventions to 
compare e.g. Atkins vs. Ornish, Atkins vs. 
LEARN diets 
<30% of energy from fat was classified as an 
LFD. Weight Watcher, Slim Fast, Rosemary 
Conley, Ornish, LEARN diets 
at least 6 
months 
Sackner-
Bernstein 2015 
(14) 
Adults with overweight/obesity as defined 
by trials’ authors. Excluded RCTs with 
subjects had co-morbidity other than 
dyslipidemia 
Total CHO intake ≤120 g/day. Institute of Medicine’s report in 2002 (≤30% of 
energy from fat/day) 
not specific 
Hashimoto 
2016 (26) 
Adults with overweight/obesity as defined 
by trials’ authors. 
No, defined as RCTs’ authors definition No, use statement 'control group' not specific 
Mansoor 2016 
(12) 
Reported healthy adults with 
overweight/obesity. Excluded RCTs 
conducted solely on subjects with BMI ≥ 
35 kg/m2 
Reference to the Atkins diet, only 20–40 g/d 
of CHO in the first phase or CHO intake of 
<20% of total energy intake. 
Conventional LFD. - not define by % or grams of 
fat content 
at least 6 
months 
BMI, body mass index; CHO, carbohydrates; HP, high protein; LCD, low-carbohydrate diets; VLCKD, very low-carbohydrate ketogenic diets; LFD, low-fat diets; LEARN, Lifestyle, Exercise, Attitudes, 
Relationships, and Nutrition diets. 
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Table 5. Methods of included systematic reviews with meta-analyses 
Authors Databases 
Search time 
frame 
Included 
studies 
No. of 
subjects 
Risk of Bias Assessment Publication bias Funding source 
Authors’ 
declaration 
Nordmann 
2006 (10) 
MEDLINE, EMBASE, PASCAL, 
GLOBAL HEALTH, HEALTH, WOS, 
and the Cochrane Library 
1 January 
1980 to 28 
February 2005 
5 447 Allocation concealment, blinded 
outcome assessment, loss to 
follow-up, and full descriptions of 
losses to follow-up and 
withdrawals were assessed. None 
of the trials used blinded outcome 
assessment for weight loss. 
Small number of trials 
precluded a sensitive 
evaluation of publication 
bias, although no 
detection of this bias by 
funnel plot. 
Swissmilk, Berne, 
Switzerland 
WS Yanci 
Jr’s salary is 
funded in 
part by the 
Robert C 
Atkins 
Foundation 
Hession 
2009 (27) 
MEDLINE, EMBASE, BIOSIS, 
Commonwealth Agricultural Bureau 
Nutrition, Abstracts and Reviews, 
CENTRAL, DARE, CRD database of 
systematic reviews, PsycINFO, WOS, 
UK National Research Register, 
CINAHL, HealthSTAR, AMED, 
SPORTDiscus, British Library Inside 
January 2000 
to March 2007 
13 1222 Methodological quality was 
assessed using a standard form 
and including intention to treat 
basis. Authors did not state the 
use of Cochrane risk of bias tool. 
In result section, they also did not 
report quality assessment of the 
included trials.  
Did not report on 
publication bias 
assessment. 
Hession M was 
supported by a 
commercial grant by 
LighterLife 
No conflict of 
interest was 
declared 
Hu 2012 
(28) 
MEDLINE, EMBASE, WOS, CDSR 1966 - 2011 23 2788 Blinding, loss to follow-up and 
intention to treat were assessed. 
Did not assess method of 
randomization and allocation 
concealment. Authors did not 
state the use of Cochrane risk of 
bias tool. In result section, they 
also did not report quality 
assessment of the included trials. 
Possible for BW, TG, 
TC, LDL, HDL, insulin 
Dr. Bazzano was 
supported by grant 
K08 HL091108 
from the NIH/ 
National Heart, 
Lung, and Blood 
Institute, USA 
No conflict of 
interest was 
declared 
Bueno 2013 
(25) 
MEDLINE, CENTRAL, ScienceDirect, 
Scopus, LILACS, SciELOand 
ClinicalTrials.gov. In addition, the 
following grey literature databases 
were searched: OpenGrey.eu, 
DissOnline.de, NYAM.org and 
ClinicalEvidence.com 
up to August 
2012 
13 1577 Cochrane Collaboration Risk of 
Bias Tool. 9 of 13 RCTs were of 
low risk of bias. Allocation 
concealment and blinding 
outcome assessment were of 
unclear to high risk of bias. 
Possible for TG level. 
No publication bias for 
BW, LDL, HDL, and 
blood pressure. 
A studentship to the 
first author by 
Conselho Nacional 
de Pesquisa e 
Desenvolvimento 
Cientı´fico e 
Tecnolo´gico 
(CNPq) grant 
130639/2011-7  
No conflict of 
interest was 
declared 
Johnston 
2014 (29) 
AMED, CDSR, CENTRAL, CINAHL, 
EMBASE, and MEDLINE from 
inception of each database to April 
2014 
up to April 
2014 
48 7286 Allocation concealment, sequence 
generation, blinding to patient and 
assessor, missing participant 
outcome data. 13 of 33 RCTs of 
LCD were high risk of bias. 
Funnel plot found 
asymmetry of weight 
loss outcome by Atkins 
diet vs. moderate 
macronutrient diets. 
Canadian Institute 
of Health Research. 
No conflict of 
interest was 
declared 
Naude 2014 
(13) 
MEDLINE (PubMed), EMBASE, 
CENTRAL 
last search on 
19 March 2014 
19 3209 Cochrane Collaboration Risk of 
Bias Tool. 50% of trials were 
unclear or high risk of bias on 
selection bias, detection bias and 
attrition bias. Six trials found to be 
influenced by funder 
Possible for BW, LDL, 
HDL, TG, TC 
Effective Health 
Care Research 
Consortium and the 
South African MRC 
No conflict of 
interest was 
declared 
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Alexandraki 
2015 (24) 
MEDLINE (PubMed) 1 January 
2001 to 
October 2014 
17 1958 Cochrane Collaboration Risk of 
Bias Tool. (16 were high risk of 
bias, 1 was at unclear risk of 
bias). Lack of allocation 
concealment and incomplete 
outcome data due to high attrition. 
Did not report on 
publication bias 
assessment. 
No financial 
relationships to 
disclose 
 
No conflict of 
interest was 
declared 
Sackner-
Bernstein 
2015 (14) 
MEDLINE (PubMed) 1966 - 2014 17 1797 No explicit risk of bias assessment 
was reported. 
Possible for BW Atkins 
Nutritionals under 
contract to ExVivos, 
LLC (ExVivos, 
LLC is owned by the 
first author). 
See 1 
Hashimoto 
2016 (26) 
MEDLINE, EMBASE and CDSR. up to 
December 
2014 
14 1805 
(1416 
after 
exclude 
dropout) 
GRADE, AMSTAR. No use of 
Cochrane Collaboration Risk of 
Bias Tool. 
Possible for BW No funding for this 
study 
See 2 
Mansoor 
2016 (12) 
MEDLINE via Ovid, EMBASE and 
CENTRAL 
up to 28 May 
2015 
11 1369 Cochrane Collaboration Risk of 
Bias Tool. One trial was high risk 
of bias. Most of trials did not 
report on allocation concealment. 
Possible for BW, TC, 
LDL, SBP, DBP and 
glucose. 
The Throne Holst 
Foundation for 
Nutrition Research 
and University of 
Oslo. 
No conflict of 
interest was 
declared 
WOS, Web of Science; CDSR, Cochrane database for systematic review; DARE, Database of Abstracts of Reviews of Effectiveness; RCT, randomised controlled trial; LCD, low-carbohydrate diet; BW, 
body weight; TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; NIH, National Institute of Health; MRC, Medical research council. 
1. Jonathan Sackner-Bernstein owns and may receive compensation from ExVivos, LLC. ExVivos, LLC provided payment to authors (DK and SK) for their role as contractors to ExVivos, LLC. 
2. Mai Asano, Masahiro Yamazaki and Michiaki Fukui have received grants, honoraria and research supports from AstraZeneca plc., Astellas Pharma Inc., Nippon Boehringer Ingelheim Co., Ltd., Daiichi 
Sankyo Co., Ltd., Eli Lilly Japan K.K., Kyowa Hakko Kirin Company Ltd., Kissei Pharmaceutical Co., Ltd., MSD K.K., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Sanwa Kagaku 
Kenkyusho Co., Ltd., Sanofi K.K., Ono Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd. 
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Table 6. Quality assessment and overall rating judgement of published systematic reviews with meta-analyses 
 
1
. 
D
id
 t
h
e
 r
e
s
e
a
rc
h
 q
u
e
s
ti
o
n
s
 a
n
d
 i
n
c
lu
s
io
n
 c
ri
te
ri
a
 
fo
r 
th
e
 r
e
v
ie
w
 i
n
c
lu
d
e
 t
h
e
 c
o
m
p
o
n
e
n
ts
 o
f 
P
IC
O
?
 
2
. 
D
id
 t
h
e
 r
e
p
o
rt
 o
f 
th
e
 r
e
v
ie
w
 c
o
n
ta
in
 a
n
 e
x
p
lic
it
 
s
ta
te
m
e
n
t 
th
a
t 
th
e
 r
e
v
ie
w
 m
e
th
o
d
s
 w
e
re
 e
s
ta
b
lis
h
e
d
 
p
ri
o
r 
to
 t
h
e
 c
o
n
d
u
c
t 
o
f 
th
e
 r
e
v
ie
w
 a
n
d
 d
id
 t
h
e
 r
e
p
o
rt
 
ju
s
ti
fy
 a
n
y
 s
ig
n
if
ic
a
n
t 
d
e
v
ia
ti
o
n
s
 f
ro
m
 t
h
e
 p
ro
to
c
o
l?
 
3
. 
D
id
 t
h
e
 r
e
v
ie
w
 a
u
th
o
rs
 e
x
p
la
in
 t
h
e
ir
 s
e
le
c
ti
o
n
 o
f 
th
e
 s
tu
d
y
 d
e
s
ig
n
s
 f
o
r 
in
c
lu
s
io
n
 i
n
 t
h
e
 r
e
v
ie
w
?
 
4
. 
D
id
 t
h
e
 r
e
v
ie
w
 a
u
th
o
rs
 u
s
e
 a
 c
o
m
p
re
h
e
n
s
iv
e
 
lit
e
ra
tu
re
 s
e
a
rc
h
 s
tr
a
te
g
y
?
 
5
. 
D
id
 t
h
e
 r
e
v
ie
w
 a
u
th
o
rs
 p
e
rf
o
rm
 s
tu
d
y
 s
e
le
c
ti
o
n
 i
n
 
d
u
p
lic
a
te
?
 
6
. 
D
id
 t
h
e
 r
e
v
ie
w
 a
u
th
o
rs
 p
e
rf
o
rm
 d
a
ta
 e
x
tr
a
c
ti
o
n
 i
n
 
d
u
p
lic
a
te
?
 
7
. 
D
id
 t
h
e
 r
e
v
ie
w
 a
u
th
o
rs
 p
ro
v
id
e
 a
 l
is
t 
o
f 
e
x
c
lu
d
e
d
 
s
tu
d
ie
s
 a
n
d
 j
u
s
ti
fy
 t
h
e
 e
x
c
lu
s
io
n
s
?
 
8
. 
D
id
 t
h
e
 r
e
v
ie
w
 a
u
th
o
rs
 d
e
s
c
ri
b
e
 t
h
e
 i
n
c
lu
d
e
d
 
s
tu
d
ie
s
 i
n
 a
d
e
q
u
a
te
 d
e
ta
il?
 
9
. 
D
id
 t
h
e
 r
e
v
ie
w
 a
u
th
o
rs
 u
s
e
 a
 s
a
ti
s
fa
c
to
ry
 
te
c
h
n
iq
u
e
 f
o
r 
a
s
s
e
s
s
in
g
 t
h
e
 r
is
k
 o
f 
b
ia
s
 (
R
o
B
) 
in
 
in
d
iv
id
u
a
l 
s
tu
d
ie
s
 t
h
a
t 
w
e
re
 i
n
c
lu
d
e
d
 i
n
 t
h
e
 r
e
v
ie
w
?
 
1
0
. 
D
id
 t
h
e
 r
e
v
ie
w
 a
u
th
o
rs
 r
e
p
o
rt
 o
n
 t
h
e
 s
o
u
rc
e
s
 o
f 
fu
n
d
in
g
 f
o
r 
th
e
 s
tu
d
ie
s
 i
n
c
lu
d
e
d
 i
n
 t
h
e
 r
e
v
ie
w
?
 
1
1
. 
If
 m
e
ta
-a
n
a
ly
s
is
 w
a
s
 p
e
rf
o
rm
e
d
 d
id
 t
h
e
 r
e
v
ie
w
 
a
u
th
o
rs
 u
s
e
 a
p
p
ro
p
ri
a
te
 m
e
th
o
d
s
 f
o
r 
s
ta
ti
s
ti
c
a
l 
c
o
m
b
in
a
ti
o
n
 o
f 
re
s
u
lt
s
?
 
1
2
. 
If
 m
e
ta
-a
n
a
ly
s
is
 w
a
s
 p
e
rf
o
rm
e
d
, 
d
id
 t
h
e
 r
e
v
ie
w
 
a
u
th
o
rs
 a
s
s
e
s
s
 t
h
e
 p
o
te
n
ti
a
l 
im
p
a
c
t 
o
f 
R
o
B
 i
n
 
in
d
iv
id
u
a
l 
s
tu
d
ie
s
 o
n
 t
h
e
 r
e
s
u
lt
s
 o
f 
th
e
 m
e
ta
-a
n
a
ly
s
is
 
o
r 
o
th
e
r 
e
v
id
e
n
c
e
 s
y
n
th
e
s
is
?
 
1
3
. 
D
id
 t
h
e
 r
e
v
ie
w
 a
u
th
o
rs
 a
c
c
o
u
n
t 
fo
r 
R
o
B
 i
n
 
in
d
iv
id
u
a
l 
s
tu
d
ie
s
 w
h
e
n
 i
n
te
rp
re
ti
n
g
/ 
d
is
c
u
s
s
in
g
 t
h
e
 
re
s
u
lt
s
 o
f 
th
e
 r
e
v
ie
w
?
 
1
4
. 
D
id
 t
h
e
 r
e
v
ie
w
 a
u
th
o
rs
 p
ro
v
id
e
 a
 s
a
ti
s
fa
c
to
ry
 
e
x
p
la
n
a
ti
o
n
 f
o
r,
 a
n
d
 d
is
c
u
s
s
io
n
 o
f,
 a
n
y
 h
e
te
ro
g
e
n
e
it
y
 
o
b
s
e
rv
e
d
 i
n
 t
h
e
 r
e
s
u
lt
s
 o
f 
th
e
 r
e
v
ie
w
?
 
1
5
. 
If
 t
h
e
y
 p
e
rf
o
rm
e
d
 q
u
a
n
ti
ta
ti
v
e
 s
y
n
th
e
s
is
 d
id
 t
h
e
 
re
v
ie
w
 a
u
th
o
rs
 c
a
rr
y
 o
u
t 
a
n
 a
d
e
q
u
a
te
 i
n
v
e
s
ti
g
a
ti
o
n
 
o
f 
p
u
b
lic
a
ti
o
n
 b
ia
s
 (
s
m
a
ll 
s
tu
d
y
 b
ia
s
) 
a
n
d
 d
is
c
u
s
s
 i
ts
 
lik
e
ly
 i
m
p
a
c
t 
o
n
 t
h
e
 r
e
s
u
lt
s
 o
f 
th
e
 r
e
v
ie
w
?
 
1
6
. 
D
id
 t
h
e
 r
e
v
ie
w
 a
u
th
o
rs
 r
e
p
o
rt
 a
n
y
 p
o
te
n
ti
a
l 
s
o
u
rc
e
s
 o
f 
c
o
n
fl
ic
t 
o
f 
in
te
re
s
t,
 i
n
c
lu
d
in
g
 a
n
y
 f
u
n
d
in
g
 
th
e
y
 r
e
c
e
iv
e
d
 f
o
r 
c
o
n
d
u
c
ti
n
g
 t
h
e
 r
e
v
ie
w
?
 
O
v
e
ra
ll
 r
a
ti
n
g
 j
u
d
g
e
m
e
n
t 
Castaneda-
Gonzalez 
2011 (22) 
Yes No Yes Partial 
yes 
No No No Partial 
yes 
No No No MA No MA  No Yes No MA No Critically low 
Dutton 2014 
(23) 
Yes No No No No No No Partial 
yes 
No No No MA No MA No No No MA Yes Critically low 
Nordmann 
2006 (10) 
Yes No No Partial 
yes 
Yes Yes No No Partial 
yes 
No Yes No Yes Yes Yes Yes Moderate 
Hession 
2009 (27) 
Yes No No Yes Yes Yes No No No No No No No No No Yes Critically low 
Hu T 2012 
(28) 
Yes No yes Partial 
yes 
Yes Yes No yes No No Yes No No Yes Yes Yes Critically low 
Bueno NB 
2013 (25) 
Yes Yes No Yes Yes Yes Yes No Yes No Yes Yes Yes Yes Yes Yes High 
Johnston 
2014 (29) 
Yes No No Yes Yes Yes No Yes Partial 
yes 
No Yes Yes Yes Yes Yes Yes Moderate 
Naude 2014 
(13) 
Yes yes No Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes High 
Alexandraki 
2015 (24) 
Yes No No No Yes Yes No Yes Yes No No Yes Yes No No Yes Critically low 
Sackner-
Bernstein 
2015 (14) 
Yes No No No No No No Yes No No No No No No Yes Yes Critically low 
Hashimoto 
2016 (26) 
Yes No No Partial 
yes 
Yes Yes No Yes No No No No Yes No Yes Yes Critically low 
Mansoor 
2016 (12) 
Yes Yes No Partial 
yes 
No No No No Yes No Yes Yes Yes Yes Yes Yes Moderate 
MA, meta-analysis 
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Table 7. Weight loss outcome (kilograms) 
Authors Pre-specified LCD 
Pre-specified LFD / 
energy-restricted diet 
Commercial 
support 
AMSTAR 2 
Quality 
6 months a 12 months a No specific time point a 
Nordmann 
2006 (10) 
60 g CHO/day 30%E fat Yes Moderate -3.3 (-5.3 to -1.4) 
I2=65%, p=0.02 
-1.0 (-3.5 to 1.5) 
I2=48%, p=0.15 
- 
Hession 2009 
(27) 
HP ketogenic 40 g 
CHO 
LCD 60 g CHO 
30%E fat Yes Critically low -4.02 (-4.54 to -3.49) 
I2=77.3%, p<0.0001 
-1.05 (-2.09 to -0.01) 
I2=10.5%, p=0.35 
- 
Hu 2012 (28) 45%E CHO 30%E fat No Critically low - - -1.0 (-2.2 to 0.2) 
I2=85.7, p<0.001 
Bueno 2013 
(25) 
VLCKD 50 g or 10%E 
CHO 
30%E fat No High - -0.91 (-1.65 to -0.17) 
I2=0%, p=0.47 
- 
Johnston 2014 
(29) 
40%E CHO 20%E fat No Moderate -0.74 (-2.31 to 0.78)b 0.02 (-1.78 to 1.79)b - 
Naude 2014 
(13) 
45%E CHO Balanced weight loss 
diet (45-65%CHO, 25-
35%F, 10-20%P) 
No High without T2DM: 
-0.74 (-1.49 to 0.01) 
I2=53%, p=0.009 
without T2DM: 
-0.48 (-1.44 to 0.49) 
I2=12%, p=0.34 
- 
     with T2DM: 
0.82 (-1.25 to 2.90) 
I2=0%, p=0.93 
with T2DM: 
0.91 (-2.08 to 3.89) 
I2=33%, p=0.21 
 
Alexandraki 
2015 (24) 
45%E CHO 30%E fat No Critically low -1.44 (-2.32 to -0.56) 
I2=91%, p<0.001 
-0.77 (-1.36 to -0.18) 
I2=48%, p=0.01 
- 
Sackner-
Bernstein 2015 
(14) 
120 g CHO 30%E fat Yes Critically low - - -2.04 (-3.15 to -0.93) 
no I2 calculated 
Hashimoto 
2016 (26) 
No; based on RCTs’ 
authors defined. 
No Yes Critically low - - -0.7 (-1.07 to -0.33) 
I2=90.3%, p<0.0001 
Mansoor 2016 
(12) 
Atkins type, 20-40 g 
CHO in first phase, or 
20%E CHO 
Conventional LFD; did 
not define % fat 
No Moderate - - -2.17 (-3.36 to -0.99) 
I2=82.2%, p<0.0001 
LCD, low-carbohydrate diet; LFD, low-fat diet; CHO, carbohydrates; E, energy; F, fat; P, protein; VLCKD, very low-carbohydrate ketogenic diet; T2DM, type 2 diabetes mellitus. 
a Weight loss are shown in mean difference between LCDs and LFD/energy-restricted diets with 95% confidence interval in parenthesis. Values represent mean weight change in 
LCD minus mean weight change in LFD; negative values indicate subjects following LCD lost more weight than those who followed LFD. 
b Results from network meta-analysis, heterogeneity was calculated from direct comparison of 4 trials comparing LCD vs. LFD at 12 months, I2=85.5%. 
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Table 8. AMSTAR quality, number of studies, number of subjects and effect size 
Published meta-analyses a 
AMSTAR 
quality score 
No. of primary 
studies 
No. of 
subjects 
Mean difference in 
weight loss (kg) b, c 
Naude 2014 (13) 14 14 1745 -0.74 
Bueno 2013 (25) 13 13 1577 -0.91 
Hu 2012 (28) 9.5 23 2788 -1.00 
Mansoor 2016 (12) 9.5 11 1369 -2.17 
Nordmann 2006 (10) 9 5 447 -3.30 
Alexandraki 2015 (24) 8 24 1958 -1.44 
Hashimoto 2016 (26) 7 14 1416 -0.70 
Hession 2009 (27) 5 9 690 -4.02 
Sackner-Bernstein 2015 (14) 4 17 1797 -2.04 
     
Items Correlation coefficient 
Mean difference in weight loss 
between LCD & LFD 
Quality score d rho = 0.41, p=0.27 
No. of primary studies e r = 0.60, p=0.09 
No. of subjects e r = 0.73, p=0.03 
a excludes one study of network meta-analysis due to indirect comparison of interventions 
b for meta-analysis with multiple time-points (e.g. 6 and 12 months) or population (e.g. with and without diabetes), 
the mean difference from highest number of included RCTs was presented and used for correlation coefficient 
analysis. 
c values represent mean weight loss in LCD minus mean weight loss in LFD; negative values indicate subjects 
following LCD lost weight greater than those who followed LFD. 
d Spearman’s rank correlation coefficient analysis 
e Pearson’s correlation coefficient analysis 
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Table 9. AMSTAR quality, effect size and citation counts 
Published meta-
analysis 
AMSTAR 
quality 
score 
Mean difference in 
weight loss (kg) a, b 
3-year citation counts after 
publication 
Impact factor (at 
year 3 of 
publication) 
Scopus Google Scholar 
Naude 2014 (13) 14 -0.74 43.90 64.10 2.806 
Bueno 2013 (25) 13 -0.91 63.47 102.32 3.311 
Hu 2012 (28) 9.5 -1.00 67.26 104.21 5.23 
Nordmann 2006 (10) 9 -3.30 133.04 188.61 9.11 
Hession 2009 (27) 5 -4.02 73.53 119.49 7.038 
a for meta-analysis with multiple time-points (e.g. 6 and 12 months) or population (e.g. with and without diabetes), the 
mean difference from highest number of included RCTs was presented and used for correlation coefficient analysis. 
b values represent mean weight loss in LCD minus mean weight loss in LFD; negative values indicate subjects following 
LCD lost more weight than those who followed LFD. 
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Table 10. Correlation coefficient between 3-year citation counts and quality, mean difference in weight loss, and impact factor. 
Items 
Spearman’s rank correlation coefficient 
Scopus Google Scholar 
Citation counts & Quality score -0.90, p=0.037 - 0.90, p=0.037 
Citation counts & Mean difference in weight loss  -0.90, p=0.037 -0.90, p=0.037 
Citation counts & Impact factor 1.00, p=0.01 1.00, p=0.01 
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Table 11. Conclusions from systematic reviews with meta-analyses of LCD vs. LFD/energy-restricted diets 
Authors Finding/Conclusion AMSTAR 2 Quality 
Naude 2014 
(13) 
Short-term weight loss was demonstrated in both LCDs and balanced diets. For Up to 2 years, weight loss and CVD risk factors were little or 
no difference in adults with overweight or obesity, with or without type 2 diabetes, who were randomised to LCDs or isoenergetic balanced 
weight loss diets. 
High 
Bueno 2013 
(25) 
The VLCKD achieved greater reductions in body weight, diastolic blood pressure, and TG, but more rises in LDL and HDL when compared to 
LFD. Therefore, VLCKD may be another option for weight management. Further studies are needed to examine the effects beyond blood 
parameters. 
High 
Johnston 
2014 (29) 
LCD and LFD programmes achieved weight loss greater than no dietary intervention through the influences of behavioural support and 
exercise. Weight loss differences among named diets were also small and of little importance. This supports recommendation of any diets that 
patients could adhere to lose weight. 
Moderate 
Mansoor 
2016 (12) 
LCDs showed inconsistent changes in two CVD risk factors – leading to more weight loss yet increased LDL. Weight loss following LCDs 
needs to be weighed against unfavourable change of increased LDL. 
Moderate 
Nordmann 
2006 (10) 
LCD was as effective as LFD for weight loss for up to 1 year. However, favourable changes in TG and HDL should be weighed against 
increased LDL. 
Moderate 
Hu 2012 (28) LCD was as effective as LFD for weight loss and metabolic risk factors, and could be recommended for weight reduction. Longer-term studies 
on clinical CVD events are needed. 
Critically low 
Alexandraki 
2015 (24) 
Weight loss could be achieved by carbohydrate restriction. However, weight loss differences between LCDs and LFDs were very small and of 
little importance. Further studies are needed. 
Critically low 
Hashimoto 
2016 (26) 
Greater weight and body fat mass loss were achieved in LCDs than control diets. Further studies are needed due to an insufficient number of 
participants and duration of study follow up period, as well as possible publication bias. 
Critically low 
Hession 2009 
(27) 
LCDs achieved greater weight loss and CVD risk reduction at 6 months, and were as effective as LFDs for up to 1 year. More long-term 
studies are needed on CVD benefits. 
Critically low 
Sackner-
Bernstein 
2015 (14) 
Although both LCDs and LFDs achieved significant weight loss and reduction of predicted ASCVD risk, LCDs were more effective for up to 2 
years. This support dietary guideline should re-consider LCD as effective and safe dietary intervention, although longer-term studies are 
needed. 
Critically low 
LCD, low-carbohydrate diet; LFD, low-fat diet; CVD, cardiovascular disease; VLCKD, very low-carbohydrate ketogenic diet; TG, triglyceride; LDL, low-density lipoprotein; HDL, high-
density lipoprotein; ASCVD, atherosclerotic cardiovascular disease. 
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Additional records identified 
through other sources  
(n = 0) 
Records after duplicates removed 
(n = 201) 
Records screened 
(n = 201) 
Records excluded 
(n = 162) 
Full-text articles assessed 
for eligibility 
(n = 39) 
Full-text articles excluded, 
with reasons (n = 27) 
 
- Not systematic review (n 
= 10) 
- No control diets (n = 3) 
- Included trials that are 
not low-carbohydrate diet 
(n = 6) 
- Did not report the 
necessary data (n = 4) 
- Not in English (n = 1) 
- Not intervention of 
interest (n = 3) 
Studies included in 
qualitative synthesis 
(n = 12) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 0) 
 
Figure 1 Flow diagram of study selection process 
WoS, Web of Sciences; CDSR, Cochrane database for systematic review 
Table S1. Search strategy for MEDLINE (Ovid) 
Search terms  
Date searched 
1. diet, carbohydrate-restricted/ or diet, paleolithic/ or ketogenic diet 
2. Weight Loss/  
3. "review"/  
4. meta-analysis/  
5. low carbohydrate diet.mp.  
6. very low carbohydrate diet.mp.  
7. zone diet.mp.  
8. sugar busters diet.mp.  
9. harcombe diet.mp.  
10. weight reduction.mp.  
11. systematic review.mp.  
12. meta analysis.mp. 
13. 1 or 5 or 6 or 7 or 8 or 9  
14. 2 or 10  
15. 3 or 4 or 11 or 12  
16. 13 and 14 and 15  
17. limit 16 to (english language and yr="2000 -Current") 
27th September 2017 
 
  
Table S2. Full-texts excluded from analysis and reasons for exclusion 
Source Reason for exclusion 
Anton et al. (1) No control diets 
Atallah et al. (2) Did not report necessary data, reported change from baseline 
Avenell et al. (3) Mostly low-fat diets 
Bravata et al. (4) Did not report necessary data, reported pooled results of mixed study designs. 
Bray et al. (5) Not systematic review 
Brehm et al. (6) Not systematic review 
Chaudhry et al. (7) No control diets, counselling is a control group 
Clifton et al. (8) Included trials that are not low-carbohydrate diets. 
Dong et al. (9) Included trials that are not low-carbohydrate diets. 
Dyson (10) Not systematic review, invited review 
Dyson (11) Not systematic review, included single arm trial 
Esposito et al. (12) Included trials that are not low-carbohydrate diets 
Franz et al. (13) Mixed intervention, not clear; low-carbohydrate diets are not the primary focus. 
Hall et al. (14) Not systematic review 
Hu et al. (15) Not systematic review, invited review 
Kirk et al. (16) No control diets 
Kosinski et al. (17) Not systematic review 
Lepe et al. (18) Included trials that are not low-carbohydrate diets. Focused on hi-protein diets 
Mancini et al. (19)  Included trials that are not low-carbohydrate diets. 
Martinez et al. (20) Not systematic review 
Mencia et al.(21) Not English language 
Santos et al. (22) Did not report necessary data, reported change from baseline 
Schwingshackl et al. (23) Low-carbohydrate diet is not a primary intervention of interest of the review, weight loss is not a primary 
outcome. 
Schwingshackl et al. (24) Included trials that are not low-carbohydrate diets. 
Soeliman et al. (25) Did not report necessary data, no weight loss outcome 
Wood (26) Not systematic review 
Wood et al. (27) Not systematic review 
Table S3. Triglyceride (mmol/L) 
Author Year 
6 months  12 months or more 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
Nordmann 2006 (28) 4 -0.25 -0.43 to -0.06 48% 0.13  3 -0.35 -0.67 to -0.03 59% 0.09 
Hession 2009 (29) 9 -0.16 -0.24 to -0.08 96.4% <0.00001  5 -0.19 -0.36 to -0.01 68.2% 0.01 
Naude 2014 (30)            
No DM HF 8 -0.03 -0.13 to 0.07 79% <0.0001  4 -0.06 -0.15 to 0.03 0% 0.9 
 HP 4 -0.15 -0.37 to 0.08 27% 0.25  2 -0.02 -0.34 to 0.31 18% 0.27 
 Total 12 -0.05 -0.14 to 0.04 72% <0.0001  6 -0.06 -0.14 to 0.03 0% 0.86 
with DM HF 1 -0.3 -0.93 to 0.33 -1 -1  1 -0.2 -0.63 to 0.23 -1 -1 
 HP 3 -0.18 -0.45 to 0.09 0% 0.87  2 0.13 -0.45 to 0.70 0% 0.44 
 Total 4 -0.20 -0.45 to 0.05 0% 0.94  3 -0.08 -0.43 to 0.26 0% 0.50 
Bueno 2013 (31) - - - - -  12 -0.18 -0.27 to -0.08 12% 0.33 
            
 No specific time points (6-24 months)       
Authors 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
      
Hu 2012 (32) 20 -0.16 -0.22 to -0.10 55.6% 0.07       
Sackner-Bernstein 
2015 (33) 
NR -0.33 -0.44 to -0.21 NR NR 
      
Mansoor 2015 (34) 11 -0.26 -0.37 to -0.15 63.8% 0.002       
NR, not reported; DM, diabetes mellitus; HF, high fat/low carbohydrate; HP, high protein/low 
carbohydrate 
1 no heterogeneity calculated, only one study. 
 
      
 
  
Table S4. LDL-cholesterol (mmol/L) 
Authors 
6 months  12 months or more 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
Nordmann 2006 (28) 4 0.14 0.03 to 0.26 0% 0.66  3 0.20 0.05 to 0.36 0% 0.8 
Hession 2009 (29) 8 0.14 0.08 to 0.2 0% 0.61  4 0.37 0.28 to 0.46 92.8% <0.00001 
Naude 2014 (30)            
No DM HF 8 0.09 -0.02 to 0.20 52% 0.04  4 0.07 -0.05 to 0.18 18% 0.3 
 HP 4 0.12 -0.11 to 0.34 0% 0.67  2 0.01 -0.26 to 0.29 0% 0.5 
 total 12 0.09 0.00 to 0.18 32% 0.14  6 0.07 -0.01 to 0.16 0% 0.5 
with DM HF 1 0.20 -0.18 to 0.58 - 1 - 1  1 0.30 -0.05 to 0.65 - 1 - 1 
 HP 4 0.02 -0.20 to 0.23 39% 0.18  3 0.05 -0.14 to 0.23 0% 0.50 
 total 5 0.06 -0.11 to 0.23 25% 0.26  4 0.10 -0.06 to 0.27 0% 0.40 
Bueno 2013 (31) - - - - -  12 0.12 0.04 to 0.20 0% 0.70 
            
 No specific time points (6-24 months)       
Authors 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
      
Hu 2012 (32) 19 0.10 0.03 to 0.17 50% 0.01       
Sackner-Bernstein 
2015 (33) 
NR 0.22 0.09 to 0.35 NR NR 
      
Mansoor 2015 (34) 11 0.16 0.003 to 0.33 84% 0.000       
NR, not reported; DM, diabetes mellitus; HF, high fat/low carbohydrate; HP, high protein/low 
carbohydrate 
1 no heterogeneity calculated, only one study. 
 
      
 
  
Table S5. HDL-cholesterol (mmol/L) 
Authors 
6 months  12 months or more 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
Nordmann 2006 (28) 4 0.12 0.04 to 0.21 75% 0.01  3 0.08 -0.02 to 0.18 79% 0.01 
Hession 2009 (29) 9 0.04 0.00 to 0.07 0% 0.62  5 0.06 0.02 to 0.11 0% 0.49 
Naude 2014 (30)            
No DM HF 8 0.03 -0.03 to 0.08 76% 0.0001  4 0.02 -0.01 to 0.06 29% 0.24 
 HP 4 0.07 -0.02 to 0.16 0% 0.95  3 0.09 0.03 to 0.15 0% 0.82 
 total 12 0.03 -0.01 to 0.08 63% 0.002  7 0.04 0.01 to 0.08 35% 0.16 
with DM HF 1 0.11 -0.13 to 0.35 - 1 - 1  1 0.16 -0.03 to 0.35 - 1 - 1 
 HP 4 -0.01 -0.06 to 0.03 0% 0.65  3 -0.04 -0.1 to 0.02 0% 0.84 
 total 5 -0.01 -0.05 to 0.04 0% 0.62  4 -0.00 -0.09 to 0.08 26% 0.25 
Bueno 2013 (31) - - - - -  12 0.09 0.06 to 0.12 9% 0.36 
            
 No specific time points (6-24 months)       
Authors 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
      
Hu Tien 2012 (32) 19 0.09 0.05 to 0.12 78.6% <0.001       
Sackner-Bernstein 
2015 (33) 
NR 0.13 0.09 to 0.17 NR NR       
Mansoor 2015 (34) 11 0.14 0.09 to 0.19 76.3% 0.000       
NR, not reported; DM, diabetes mellitus; HF, high fat/low carbohydrate; HP, high protein/low 
carbohydrate 
1 no heterogeneity calculated, only one study. 
 
      
 
  
Table S6. Total cholesterol (mmol/L) 
Authors 
6 months  12 months or more 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
Nordmann 2006 (28) 4 0.23 0.08 to 0.37 0% 0.48  3 0.26 0.09 to 0.42 0% 0.63 
Hession 2009 (29) 9 0.19 0.1 to 0.28 0% 0.84  4 0.2 -0.1 to 0.3 46% 0.14 
Naude 2014 (30)            
No DM HF 8 0.06 -0.04 to 0.16 30% 0.19  4 0.04 -0.11 to 0.19 30% 0.23 
 HP 4 0.15 -0.10 to 0.40 29% 0.24  2 0.1 -0.17 to 0.38 0% 0.44 
 total 12 0.08 -0.02 to 0.17 26% 0.19  6 0.06 -0.03 to 0.16 0% 0.42 
with DM HF 1 0.2 -0.35 to 0.75 - 1 - 1  1 0.40 -0.05 to 0.85 - 1 - 1 
 HP 4 -0.00 -0.32 to 0.31 56% 0.08  3 0.03 -0.18 to 0.25 0% 0.54 
 total 5 0.04 -0.21 to 0.30 43% 0.14  4 0.10 -0.12 to 0.31 9% 0.35 
            
 No specific time points (6-24 months)       
Authors 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
      
Hu Tien 2012 (32) 15 0.07 0.02 to 0.12 20% 0.45       
Sackner-Bernstein 
2015 (33) 
NR 0.24 0.07 to 0.41 NR NR       
Mansoor 2015 (34) 4 0.26 -0.09 to 0.62 82% 0.001       
NR, not reported; DM, diabetes mellitus; HF, high fat/low carbohydrate; HP, high protein/low 
carbohydrate 
1 no heterogeneity calculated, only one study. 
 
      
 
  
Table S7. Blood glucose (mmol/L) 
Authors 
6 months  12 months or more 
No. of 
included 
studies 
mean difference 95%CI I2 
p-value for 
I2 
 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
Hession 2009 (29) 6 -0.01 no unit -0.15 to 0.13 47.5% 0.09  4 -0.05 -0.2 to 0.11 0% 0.56 
Naude 2014 (30)            
No DM HF 6 0 -0.12 to 0.13 66% 0.01  4 0.07 -0.1 to 0.23 60% 0.06 
 HP 4 0.18 0.02 to 0.35 0% 0.74  2 -0.21 -0.44 to 0,02 0% 0.33 
 total 10 0.05 -0.05 to 0.15 54% 0.02  6 -0.00 -0.16 to 0.16 64% 0.02 
with DM total 2 0.69 -0.02 to 1.40 18% 0.27  1 0.00 -1.94 to 1.94 - 1 - 1 
Bueno 2013 (31) - - - - -  8 -0.08 -0.18 to 0.02 0% 0.88 
            
 No specific time points (6-24 months)       
Authors 
No. of 
included 
studies 
mean difference 95%CI I2 
p-value for 
I2 
      
Hu 2012 (32) 14 -0.02 -0.11 to 0.07 41.2% 0.06       
Mansoor 2015 (34) 7 -0.23 -0.55 to 0.08 91.5% 0.000       
DM, diabetes mellitus; HF, high fat/low carbohydrate; HP, high protein/low carbohydrate 
1 no heterogeneity calculated, only one study. 
 
      
 
  
Table S8. Insulin 
Authors time point 
number of included 
studies 
mean difference 95%CI I2 p-value for I2 
Hu 2012 (32) 6-24 months 12 -0.1 IU/mL -0.8 to 0.6 7.8% 0.29 
Bueno 2013 (31) >/= 12 months 6 -5.52 pmol/l -13.62 to 2.57 26% 0.24 
Mansoor 2015 (34) 6-24 months 7 -0.11 mU/l -1.49 to 1.26 87.5% <0.001 
 
Table S9. HbA1c (%) 
Authors 
6 months  12 months or more 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2  
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
Naude 2014 (30)            
with DM HF 1 0.4 -0.50 to 1.30 - 1 - 1  1 0.10 -1.46 to 1.66 - 1 - 1 
 HP 4 0.18 -0.02 to 0.39 0% 0.81  3 0.01 -0.29 to 0.30 0% 0.99 
 total 5 0.19 -0.00 to 0.39 0% 0.88  4 0.01 -0.28 to 0.30 0% 1.00 
Bueno 2013 (31) - - - - -  4 -0.24 -0.55 to 0.06 0% 0.59 
DM, diabetes mellitus; HF, high fat/low carbohydrate; HP, high protein/low carbohydrate 
1 no heterogeneity calculated, only one study. 
 
 
  
Table S10. Systolic blood pressure (mmHg) 
Authors 
6 months  12 months or more 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
Nordmann 2006 (28) 5 -2.4 -4.9 to 0.1 0% 0.76  3 -1.3 -4.5 to 2 0% 0.57 
Hession 2009 (29) 6 -1.35 -3.25 to 0.56 19.9% 0.28  5 -2.19 -4.35 to -0.03 28.2% 0.23 
Naude 2014 (30)            
No DM HF 5 -1.41 -2.9 to 0.08 0% 0.64  4 -1.38 -4.07 to 1.32 35% 0.2 
 HP 2 -0.79 -7.32 to 5.74 27% 0.24  2 -6.45 -21.01 to 8.10 77% 0.04 
 total 7 -1.26 -2.67 to 0.15 0% 0.64  6 -2.00 -5.00 to 1.00 48% 0.09 
with DM HF 1 -2.00 -9.41 to 5.41 - 1 - 1  1 1.00 -5.79 to 7.79 - 1 - 1 
 HP 3 1.30 -3.46 to 6.06 55% 0.11  3 0.07 -3.87 to 4.02 0% 0.52 
 total 4 0.61 -3.14 to 4.36 40% 0.17  4 0.31 -3.10 to 3.72 0% 0.71 
Bueno 2013 (31) - - - - -  11 -1.47 -3.44 to 0.50 33% 0.13 
            
 No specific time points (6-24 months)       
Authors 
No. of 
included 
studies 
mean 
difference 
95%CI I2 
p-value for 
I2 
      
Hu 2012 (32) 18 -1 -3.5 to 1.5 91.7% <0.001       
Sackner-Bernstein 
2015 (33) 
NR -1.7 -3.5 to 0.2 NR NR       
Mansoor 2015 (34) 8 -1.02 -2.98 to 0.94 63.1% 0.008       
NR, not reported; DM, diabetes mellitus; HF, high fat/low carbohydrate; HP, high protein/low 
carbohydrate 
1 no heterogeneity calculated, only one study. 
 
      
 
  
Table S11. Diastolic blood pressure (mmHg) 
Authors 
6 months  12 months or more 
No. of 
included 
studies 
mean 
difference 
95%CI I-square 
p-value for 
I-sq 
 
No. of 
included 
studies 
mean 
difference 
95%CI I-square 
p-value for 
I-sq 
Nordmann 2006 (28) 5 -1.8 -3.7 to 0.1 17% 0.3  3 -0.4 -2.6 to 1.7 1% 0.37 
Hession 2009 (29) 6 -0.49 -1.85 to 0.86 10.6% 0.35  4 -0.76 -2.43 to 0.90 1.1% 0.39 
Naude 2014 (30)            
No DM HF 6 -0.39 -1.65 to 0.87 34% 0.18  4 0.01 -1.67 to 1.69 3% 0.23 
 HP 2 0.85 -5.97 to 7.68 77% 0.04  2 -1.21 -8.89 to 6.48 64% 0.09 
 total 8 -0.08 -1.53 to 1.36 51% 0.05  6 0.03 -1.68 to 1.62 29% 0.22 
with DM HF 1 -2 -6.02 to 2.02 - 1 - 1  1 0.00 -4.82 to 4.82 - 1 - 1 
 HP 3 1.63 -1.18 to 4.43 32% 0.23  3 0.11 -2.15 to 3.26 0% 0.96 
 total 4 0.77 -1.77 to 3.30 39% 0.18  4 0.09 -1.95 to 2.13 0% 0.99 
Bueno 2013 (31) - - - - -  11 -1.43 -2.49 to -0.37 3% 0.41 
            
 No specific time points (6-24 months)       
Authors 
No. of 
included 
studies 
mean 
difference 
95%CI I-square 
p-value for 
I-sq 
      
Hu 2012 (32) 18 -0.7 -1.6 to 0.2 0.408 0.04       
Mansoor 2015 (34) 
8 -1.01 -2.75 to 0.74 77.9% 0.000       
DM, diabetes mellitus; HF, high fat/low carbohydrate; HP, high protein/low carbohydrate 
1 no heterogeneity calculated, only one study. 
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